The preclinical-stage pharmaceutical company focuses on discovering, developing, and commercializing medicines to treat neurodevelopmental and cognitive disorders. Their lead candidate, IAMA-6, is a first-in-class selective-NKCC1 inhibitor that can alleviate learning and memory difficulties typical of patients with Down syndrome and behavioral manifestations of the autism spectrum. Other compounds in their pipeline target refractory epilepsy and brain disorders characterized by neuronal imbalance. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline.